A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2016
At a glance
- Drugs LJN 452 (Primary)
- Indications Primary bile acid malabsorption
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.
- 22 Mar 2016 New trial record